Related Experiment Videos

Chemical synthesis and biological activity of a novel fluorescent etoposide derivative

J S Lazo1, T Li, E S Woo

  • 1Department of Pharmacology, University of Pittsburgh, PA 15261, USA. lazo@pop.pitt.edu or yalowich+@pitt.edu

Insights

Researchers developed a fluorescent etoposide (Bodipy-etoposide) to study drug entry and distribution. While less potent, it showed similar resistance patterns and cellular uptake in resistant cells, aiding research into etoposide-like compounds.

Area of Science:

  • Pharmacology and Molecular Biology
  • Cancer Therapeutics
  • Drug Delivery and Cellular Uptake

Background:

  • Etoposide is an antineoplastic drug that functions by inhibiting DNA topoisomerase II (topo II).
  • The mechanisms governing etoposide's cellular entry and subcellular localization are not fully understood.
  • Understanding these factors is crucial for optimizing etoposide's therapeutic efficacy and overcoming resistance.

Purpose of the Study:

  • To synthesize a novel fluorescently labeled etoposide analog, Bodipy-etoposide, for studying drug disposition.
  • To investigate the cellular uptake, subcellular distribution, and activity of Bodipy-etoposide in cancer cells.
  • To assess the utility of Bodipy-etoposide as a tool for probing etoposide-like compound behavior in live cells.

Main Methods:

  • Synthesis of Bodipy-etoposide by conjugating a Bodipy fluorophore to an etoposide precursor.
  • Assessment of Bodipy-etoposide's ability to stabilize topo II-DNA complexes in isolated nuclei.
  • Evaluation of growth inhibitory activity in human leukemia (K562) and prostate carcinoma (DU-145) cells.
  • Analysis of cellular association and subcellular localization using flow cytometry and confocal laser scanning microscopy.
  • Comparison of Bodipy-etoposide activity and uptake in etoposide-sensitive and etoposide-resistant cell lines.

Main Results:

  • Bodipy-etoposide retained the ability to stabilize topo II-DNA complexes but was less potent and efficacious than etoposide.
  • Growth inhibition by Bodipy-etoposide was approximately 200-fold less than etoposide in tested cell lines.
  • Etoposide-resistant leukemia cells exhibited cross-resistance to Bodipy-etoposide.
  • Flow cytometry showed concentration-dependent Bodipy-etoposide cell association, with no significant difference between resistant and sensitive cells.
  • Confocal microscopy revealed significant cytoplasmic perinuclear localization of Bodipy-etoposide.

Conclusions:

  • Bodipy-etoposide serves as a valuable fluorescent probe for investigating the cellular entry and subcellular distribution of etoposide.
  • The drug exhibits reduced potency but maintains cross-resistance patterns observed with etoposide.
  • The findings suggest that Bodipy-etoposide can be used to study the disposition of etoposide-like compounds in live cellular models.

Related Concept Videos